CPC C07K 14/5443 (2013.01) [A61K 38/1774 (2013.01); A61K 38/1793 (2013.01); A61K 38/2086 (2013.01); C07K 14/7051 (2013.01); C07K 14/7155 (2013.01); C07K 16/28 (2013.01); C12N 15/09 (2013.01); C12N 15/62 (2013.01); G01N 33/56977 (2013.01); A61K 38/00 (2013.01); C07K 16/18 (2013.01); C07K 2319/00 (2013.01); C07K 2319/31 (2013.01); C07K 2319/33 (2013.01); C07K 2319/74 (2013.01); C07K 2319/75 (2013.01); C12P 21/00 (2013.01)] | 17 Claims |
1. A method of treatment for cancer or viral infection in a mammal in need thereof, the method comprising administering an effective amount of a soluble fusion protein complex comprising two soluble proteins, wherein the first soluble protein comprises:
(a) a fusion protein comprising a first biologically active polypeptide covalently linked to an interleukin-15 (IL-15) polypeptide, or
(b) an IL-15 polypeptide; and
the second soluble protein comprises a fusion protein comprising:
(c) a second biologically active polypeptide covalently linked to (d) an interleukin-15 receptor alpha (IL-15Ra) polypeptide;
wherein the first and/or second biologically active polypeptides comprise cytokines, chemokines, growth factors or receptor binding domains thereof;
wherein the IL-15 domain of the first soluble protein binds to the IL-15Ra domain of the second soluble protein to form the soluble fusion protein complex; and
wherein the first biologically active polypeptide is different than an IL-15Ra polypeptide, and the second biologically active polypeptide is different than an IL-15 polypeptide.
|